v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative Effect, Period of Adoption, Adjustment
Treasury Stock
Balance at beginning of period ( in shares) at Dec. 31, 2019 [1]     366.4            
Balance at beginning of period at Dec. 31, 2019 $ 882.6 [1] $ (174.5) $ 0.4 [1] $ 1,675.6 [1] $ (242.3) $ 2.3 [1] $ (695.7) [1] $ 67.8 $ (100.0) [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under equity incentive plans (in shares)     4.2            
Issuance of common stock under equity incentive plans 0.3     0.3          
Issuance of common stock for employee stock purchase plan (in shares)     0.3            
Issuance of common stock for Employee Stock Purchase Plan 15.0     15.0          
Tax benefit related to Senior Convertible Notes 45.6     45.6          
Repurchase and conversions of notes (in shares)     13.5            
Repurchase and conversions of Notes 112.9     112.9          
Share-based compensation expense 119.4     119.4          
Net income 549.7 [2],[3]           549.7    
Other comprehensive income (loss), net of tax 0.9 [4]         0.9      
Balance at end of period (in shares) at Dec. 31, 2020 [1]     384.4            
Balance at end of period at Dec. 31, 2020 [1] 1,551.9   $ 0.4 1,726.5   3.2 (78.2)   (100.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under equity incentive plans (in shares)     2.9            
Issuance of common stock under equity incentive plans 0.0                
Issuance of common stock for employee stock purchase plan (in shares)     0.3            
Issuance of common stock for Employee Stock Purchase Plan 20.3     20.3          
Tax benefit related to Senior Convertible Notes $ (2.0)     (2.0)          
Repurchase and conversions of notes (in shares) 0.8   1.4            
Repurchase and conversions of Notes $ 57.2     32.6         24.6
Benefit of note hedge upon conversions of 2023 Notes (in shares) (1.0)   (1.0)            
Shares issued in connection with 2023 Notes conversions $ 0.0     130.8         (130.8)
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 0.0                
Purchases of treasury stock (in shares) 0.0                
Share-based compensation expense $ 113.4     113.4          
Collaborative research and development fee 87.1     87.1          
Net income 216.9 [2],[3]           216.9    
Other comprehensive income (loss), net of tax $ (2.7) [4]         (2.7)      
Balance at end of period (in shares) at Dec. 31, 2021 388.0   388.0 [1]            
Balance at end of period at Dec. 31, 2021 [1] $ 2,042.1 [5]   $ 0.4 2,108.7   0.5 138.7   (206.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock under equity incentive plans (in shares)     1.6            
Issuance of common stock under equity incentive plans 0.0                
Issuance of common stock for employee stock purchase plan (in shares)     0.3            
Issuance of common stock for Employee Stock Purchase Plan 22.5     22.5          
Tax benefit related to Senior Convertible Notes $ (0.4)     (0.4)          
Repurchase and conversions of notes (in shares) 0.4   0.4            
Repurchase and conversions of Notes $ 17.4     4.2         13.2
Benefit of note hedge upon conversions of 2023 Notes (in shares) (0.3)   (0.3)            
Shares issued in connection with 2023 Notes conversions $ 0.0     33.5         (33.5)
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 2.9   2.9            
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs $ (0.1)     (189.3)         189.2
Purchases of treasury stock $ (557.7)               (557.7)
Purchases of treasury stock (in shares) (6.6)   (6.6)            
Share-based compensation expense $ 126.5     126.5          
Capitalization of sales-based milestones 152.4     152.4          
Net income 341.2           341.2    
Other comprehensive income (loss), net of tax $ (12.1)         (12.1)      
Balance at end of period (in shares) at Dec. 31, 2022 386.3   386.3            
Balance at end of period at Dec. 31, 2022 $ 2,131.8   $ 0.4 $ 2,258.1   $ (11.6) $ 479.9   $ (595.0)
[1] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis on January 1, 2020. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[2] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[3] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[4] * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.
[5] * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information.